 |
|
|
| |
Phase 2 Once-Weekly Dose Optimization for Ulonivirine in Combination with Islatravir 2 mg
|
| |
| |
IAS 2025, the 13th IAS conference on HIV Science
Michelle Pham*, Gillian Gillespie, Tracy L. Diamond, Stephanie Klopfer, Randolph P. Matthews, Martin Johnson#, Ryan Vargo
Merck & Co., Inc., Rahway, NJ, USA
*Presenting author
#An employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, at the time the study was conducted
|
| |
|
|
|
|
|
